NorthWest Biotherapeutics Inc (NWBO)

[Sojourner55]

However the citations she listed (7,14) about potential patient selection bias does not say anything about patient selection bias unless I'm missing something or she just pulled 2 citations hoping no one would fact check it.

While the interim analysis from the trial showed an eight-month OS survival benefit for the addition of DCVax-L to SoC, key stakeholders in the field have indicated potential patient selection bias (7,14).

7. The microenvironmental landscape of brain tumors
Daniela F. Quail1 and Johanna A. Joyce2,3,*

DC vaccines are likewise gaining significant clinical attention as an alternative strategy to stimulate T cell responses (Anguille et al., 2014; Palucka and Banchereau, 2012). DCVax-L, an autologous tumor lysate-pulsed DC vaccine, is furthest along in this regard, with early clinical trials reporting a median survival of 31.4 months in glioblastoma patients (Prins et al., 2011) – an improvement over historical controls of 14.6 months for the standard of care comprising radiation and temozolomide chemotherapy (Stupp et al., 2005). As a result, Phase III trials have now been initiated (ClinicalTrials.gov identifier: NCT00045968) (Table 1).

And

14 is a press release from Celldex and I don't see anything about patient selection bias.

14. https://ir.celldex.com/news-releases/news-release-details/data-safety-and-monitoring-board-recommends-celldexs-phase-3